Longevity: The Science and Business of Aging

• Up to $144M over five years, structured as milestone-based contracts rather than grants (Longevity.Technology, 25 Feb 2026).
• Teams include Cambrian BioPharma (up to $30.8M, an oral rapamycin analog), Linnaeus Therapeutics (up to $22M), and a UT Health San Antonio phase 3 hybrid trial of an SGLT2 inhibitor, rapamycin and semaglutide.
• Stanford and Columbia work on biomarkers, harmonized data and endpoints; the aim is early surrogate endpoints that show an aging shift within one to three years.

Loyal announced a $100M Series C led by age1 on 11 Feb 2026 (Loyal press release), bringing total capital to over $250M. Its LOY-002 dog pill has had the effectiveness and target animal safety sections accepted by FDA CVM for Expanded Conditional Approval (safety accepted January 2026); the third requirement was in progress and Loyal planned to submit it later in 2026. The 1,300-dog STAY study had completed enrollment and has no final results yet (Fortune, 11 Apr 2026). No approval was found as of the sources read.

Life Biosciences announced on 9 Jun 2026 that the first participant was dosed in a Phase 1 trial of ER-100 (OSK partial reprogramming) for open-angle glaucoma and NAION, registered as NCT07290244. The trial primarily tests safety and tolerability, with visual function as additional endpoints (Life Biosciences release).

• NewLimit: $435M Series C, 2 Jun 2026, to take its first epigenetic reprogramming medicine toward human trials (Cure longevity funding tracker, Jul 2026).
• Retro Biosciences: initial close of a new round at a $1.8B pre-money valuation, 22 May 2026 (same tracker); amount undisclosed.
• Life Biosciences: $80M Series D, 8 Apr 2026 (same tracker).

Not refreshed: capital-raised chart totals for Calico, Altos, NewLimit, eGenesis and Life Biosciences (cumulative figures could not be reconciled with the new rounds); Altos Labs 2026 funding (nothing found); TriviumVet cat approval status; organ-transplant counts; pharma pipeline percentages; demographic and GDP figures; the 30-year trial estimate.

• Aging is one process. We treat it as a single risk factor, not a list of diseases.
• Separate proof from hype. We flag what is shown in mice, in humans, and merely claimed.
• Follow the money and the rules. The bottleneck is regulatory and financial, not biological.
• Every figure is dated. Sourced to primary studies; estimates are marked as such.

Aging is the largest shared risk factor for death, disease and cost on Earth, and a century of animal data says it can be slowed. Yet not one drug is approved to treat it. The gap between what the biology allows and what the market has delivered is the entire investment story.

The single biggest risk factor for a heart attack is not smoking, blood pressure or cholesterol. It is age. A healthy 75-year-old is likelier to have a heart attack than a 20-year-old smoker with high blood pressure, high cholesterol and diabetes. Age is the master variable.

A line chart on a log scale plots annual risk of death (%) against age, from 25 to 100. The line climbs steadily across the whole range, rising by roughly two orders of magnitude between age 25 and age 100. Source: Gompertz-Makeham law of mortality.

There are almost as many theories of aging as there are researchers, but nearly all agree the genome sets the range, and damage fills it in. From a 58-day worm to a ~392-year shark, the same molecular parts yield wildly different lifespans. What divides the theories is whether aging is a program to switch off or damage to clean up.

1. 1825Gompertz's law: mortality found to double roughly every 8 years.
2. 1935Calorie restriction: underfed rodents live 30-50% longer, the first reliable lever.
3. 2006Yamanaka factors: adult cells can be reset toward youth; the seed of reprogramming.
4. 2009Rapamycin (NIH ITP): extends mouse lifespan even when started late.
5. 2025Drug combinations: rapamycin + trametinib add ~30% to mouse lifespan.

It works even when started late in life, by damping mTOR, the cell's nutrient-and-growth sensor, so cells shift from growth toward repair. Yet it has never run a large human aging trial: it is off-patent, so no company will fund one.

• The gold standard. NIH's Interventions Testing Program retests claims across three independent labs.
• Most claims fail. Resveratrol, fish oil, curcumin and nicotinamide riboside showed no mouse lifespan benefit.
• Rapamycin passed. One of the very few compounds to replicate, repeatedly.
• Combinations can stack. Rapamycin + trametinib beat either drug alone (~30%).

No drug has ever been approved, anywhere, to treat aging, not because the science says it can't be done, but because the trial to prove it is nearly impossible to run. Aging isn't a recognized disease, all-cause-mortality trials take decades, and by the time one finished the patent would be long gone.

A trial of 3,000 40-year-olds testing a drug that cuts death risk 20% would need roughly three decades and $300-350M to reach statistical significance, long after the patent expires. That math, not a lack of will, is why the trials don't happen.

A two-by-two map. The horizontal axis runs from 'Buys time' to 'Stops & reverses aging'; the vertical axis runs from 'No deep theory' to 'Requires understanding aging'. Traditional Pharma and Advanced Bioengineering sit in the 'requires understanding aging' half (Traditional Pharma toward 'buys time', Advanced Bioengineering toward 'stops & reverses'); Biostasis and Replacement sit in the 'no deep theory' half (Biostasis toward 'buys time', Replacement toward 'stops & reverses').

• Reuses the machinery. Leans on today's drug, regulatory and commercial infrastructure.
• Back-door drugs. Rapamycin, SGLT2 inhibitors, GLP-1s: approved for disease, studied for aging.
• Loyal (dogs). STAY trial in 1,300 senior dogs, enrollment complete: the first FDA-recognized aging study. Safety and effectiveness sections accepted; manufacturing section still pending (Feb 2026).
• TriviumVet (cats). Extended-release rapamycin won FDA conditional approval, 2025.

1. Yamanaka factors (2006): four proteins reset an adult cell toward a stem-like state; Nobel 2012.
2. Full to partial: brief exposure rejuvenates molecular markers without erasing cell identity.
3. Animal results: muscle and nerve regeneration, less scarring, ~7-12% longer life in normal mice.
4. First human trial (2026): Life Biosciences dosed its first patient in June 2026 (ER-100, glaucoma and NAION), not whole-body aging.

• The idea. Cool the body until molecular decay effectively stops.
• Proof it scales down. A rat kidney frozen to -150C, stored 100 days, was transplanted and worked (2023).
• Nature's precedent. Wood frogs freeze solid; 46,000-year-old worms revived from permafrost.
• The reality. 500+ people are already preserved; whole-body recovery remains unproven.

1. Billionaire and VC capital
2. Elite talent and platforms
3. Bigger, faster experiments
4. Credible milestones
5. Higher valuations, more capital

About $1-2B a year worldwide, less than a single big drug's Phase III budget. Alzheimer's research alone receives roughly 8x more than the study of aging itself, despite aging being its largest risk factor.

• Credibility. Decades of over-claiming left the field a snake-oil reputation.
• No precedent. No regulator has ever approved a drug for aging.
• No pathway. Aging isn't a recognized indication; no trial guidance exists.
• No constituency. Patients rally for named diseases, not for 'aging' itself.
• Capital defaults to disease. So even aging-derived drugs are tested one disease at a time.

The PROSPR program (up to $144M in contracts to seven teams, announced February 2026) is building an 'intrinsic capacity' score from wearables, blood biomarkers and function tests to predict 20-year outcomes, a possible stand-in for the impossible mortality trial. It plans to test rapamycin, SGLT2 inhibitors and GLP-1s against it.

We can already slow aging in a mouse and revive a worm frozen for forty-six thousand years. What we cannot yet do is run the trial that would let us sell the cure, and that, not the biology, is the bottleneck.

• Institute for Health Metrics and Evaluation (IHME): Global Burden of Disease (2023).
• Lopez-Otin et al.: 'Hallmarks of Aging: An Expanding Universe,' Cell (2013; 2023).
• NIH Interventions Testing Program: independent mouse lifespan results (2004-2025).
• Nature: rapamycin and rapamycin + trametinib lifespan studies (2009; 2025).
• Cochrane Library; Aging Cell: statin, SGLT2 and GLP-1 all-cause mortality analyses.
• age1: 1st Annual Pharma Aging Report Card (2025).
• ARPA-H: PROSPR program announcement (2026).
• Figures marked 'est.' or 'illustrative' are compilations of the above.